Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

NCT03558087 is registered in ClinicalTrials.gov with Matthew Galsky as lead sponsor.

NCT NCT03558087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03558087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Lead sponsor
Matthew Galsky
Phase
Phase 2
Overall status
Completed
Start date
July 13, 2018
Completion date
March 7, 2024
Enrollment
76 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer